Epidemiology of Renal Cancer in Developing Countries: Review of the Literature
Overview
Affiliations
Introduction: Renal cell carcinoma (RCC) is the ninth most common cancer in men, and the 14th most common cancer in women. It has been reported that the incidence of RCC is rising. These changes are more common in developed countries because of better screening programs and disease registry. The aim of this article is to review the epidemiology of RCC around the world.
Methods: A literature review of four databases was performed: PubMed, Embase, Lilacs, and Scielo. Studies of incidence, prevalence, mortality, and survival of RCC were taken from different countries. Studies included were published in the last 10 years. Two reviewers independently selected the studies.
Results: A total of 5275 references were reviewed by title and abstract. In the end, 42 references were selected for full-text review. The global incidence and prevalence of cancer vary. The highest incidence was described in North America and Northern Europe. In Canada, by 2007 the incidence was 17.9/100 000 and 10.3/100 000 in males and females, respectively. Developing countries like Colombia have fewer incidence rates, with less information in poor-income areas.
Conclusions: We have seen a rise in the incidence and mortality of RCC globally. There is an association between RCC and smoking, obesity, hypertension, and socioeconomic status. Seeing the epidemiological data from some regions in developing countries and the lack of specialists in those places, it can be deduced there is underreporting of the disease that reveals the need to improve both surveillance and disease registration programs, especially in these countries.
Contribution and expression of renal drug transporters in renal cell carcinoma.
Zuo Y, Li T, Yang S, Chen X, Tao X, Dong D Front Pharmacol. 2025; 15:1466877.
PMID: 40034145 PMC: 11873565. DOI: 10.3389/fphar.2024.1466877.
Barrera-Juarez E, Halun-Trevino A, Ruelas-Martinez M, Madero-Frech A, Camacho-Trejo V, Estrada-Bujanos M Cancer Causes Control. 2024; .
PMID: 39514146 DOI: 10.1007/s10552-024-01891-3.
Bulut E, Kupeli A, Ramazanoglu M, Aydin H, Sibal I, Bicaklioglu F Turk J Med Sci. 2024; 54(4):784-791.
PMID: 39295621 PMC: 11407362. DOI: 10.55730/1300-0144.5850.
Vamesu S, Ursica O, Milea S, Deacu M, Aschie M, Mitroi A Medicina (Kaunas). 2024; 60(7).
PMID: 39064555 PMC: 11279004. DOI: 10.3390/medicina60071126.
Janes W, Fagan M, Andrews J, Harvey D, Warden G, Johnston P Can Urol Assoc J. 2024; 18(4):E113-E119.
PMID: 38381938 PMC: 11034969. DOI: 10.5489/cuaj.8519.